Sircar, Geetabali <br/><br/>
Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.  [electronic resource] 

 -  Rheumatology (Oxford, England)  12 2018 
 - 2106-2113 p.  digital 
<br/><br/> Publication Type: Equivalence Trial; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1462-0332 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/key213  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antirheumatic Agents--therapeutic use<br/>Cyclophosphamide--therapeutic use<br/>Disease Progression<br/>Female<br/>Humans<br/>Lung--pathology<br/>Lung Diseases, Interstitial--drug therapy<br/>Male<br/>Rituximab--therapeutic use<br/>Scleroderma, Diffuse--complications<br/>Severity of Illness Index<br/>Skin--pathology<br/>Treatment Outcome<br/>Vital Capacity--drug effects<br/>Walk Test